GlassScriptPhysician profile
Jaime Alvarez
NPI 1053379115
$11,418.82
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,647 · 2020: $1,098 · 2021: $2,345 · 2022: $2,418 · 2023: $879 · 2024: $31.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $910.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $3,466.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,892.77 | 2019-2024 | Trelegy Ellipta, Nucala |
| Octapharma USA, INC. | $1,073.85 | 2019-2023 | Cutaquig |
| Takeda Pharmaceuticals U.S.A., INC. | $1,003.66 | 2020-2023 | Cuvitru, Takhzyro |
| Genzyme Corporation | $812.65 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $775.23 | 2019-2023 | Fasenra |
| Regeneron Healthcare Solutions, INC. | $707.79 | 2019-2023 | Dupixent |
| Alk-Abello, INC | $219.01 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $184.32 | 2019-2022 | |
| Orthofix Medical, INC. | $140.00 | 2019 | |
| Genentech USA, INC. | $136.66 | 2019-2023 | Xolair |
| Aimmune Therapeutics, INC. | $119.32 | 2020-2022 | |
| Shire North American Group INC | $111.54 | 2019 | |
| Csl Behring | $109.70 | 2021-2023 | Haegarda |
| Kaleo, INC. | $99.80 | 2020-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $99.38 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $84.26 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $71.30 | 2019-2020 | |
| Amgen INC. | $64.31 | 2021-2022 | |
| Pharming Healthcare, INC. | $54.23 | 2021-2022 | |
| Grifols USA, LLC | $41.91 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $41.85 | 2019-2023 | Verquvo |
| Gilead Sciences, INC. | $34.30 | 2020-2021 | |
| Leo Pharma INC. | $26.40 | 2023 | Adbry |
| Advanced Respiratory, INC | $18.55 | 2019 | |
| Baxter Healthcare | $16.02 | 2022 | |
| Uswm, LLC | $14.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaime Alvarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.